Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (October 2021)
14 slides from Genetic Signatures's investor presentation, October 2021
Slide 1: Investor Presentation October 2021
Investor Presentation October 2021
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer SEPTEMBER OCTOBER 2021 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and comprises written materials/slides for a verbal presentation concerning the Company and should be read in that context. Th
Slide 3: Company Summary
Investor DOCUMENT Presentation TITLE SEPTEMBER OCTOBER 2021 Company Summary Novel 3base™ technology – rapid, low cost and accurate EasyScreen™ test kits available for sale in most major markets 1Q FY22 sales $12.4m, FY21 $28.3m YoY growth since listing ‒ 4 year CAGR 93% Customers – high throughput l
Slide 4: EasyScreen Detection Kits
Trusted & Proven Technology Investor DOCUMENT Presentation SEPTEMBER TITLE OCTOBER 2021 A ‘Syndromic Screening’ approach allows users to test a broad range of clinically relevant pathogens based on patient symptoms, helping clinicians make accurate diagnoses EasyScreen™ Detection Kits Streamlined un
Slide 5: Financial Summary - Sales
Investor DOCUMENT Presentation TITLE Financial Summary - Sales SEPTEMBER OCTOBER 2021 Revenue from sales (A$m) Continued Strong Revenue Growth Record quarterly revenue $12.4m from sales Demand for COVID tests continues due to ongoing outbreaks New instrument placements continue to support future dem
Slide 6: Financial Summary - Cashflow
Investor DOCUMENT Presentation TITLE Financial Summary - Cashflow SEPTEMBER OCTOBER 2021 A$'000s 1Q FY22 Positive Q1 cashflow of $2.9m Receipts from customers 10,340 Receipts from customers - $10.3m Payments to suppliers and employees (7,302) ‒ Trade receivables balance @ 30 Sep $8.1m, Other 3 up $2
Slide 7: Product Portfolio and Development Pipeline
Product Portfolio and Development Pipeline Investor DOCUMENT Presentation SEPTEMBER TITLE OCTOBER 2021 ~$627m1 / $6.3bn SARS-CoV-2 p.a2 *FDA for enteric protozoa kit ~$537m p.a1 underway ~$1.9bn p.a1 7 1. Global market size (A$m per annum) - Kalorama Information, Molecular Testing Markets for Infect
Slide 8: Beyond SARS-CoV-2
Investor DOCUMENT Presentation TITLE Beyond SARS-CoV-2 SEPTEMBER OCTOBER 2021 Initially developed SARS-CoV-2 test based on existing expertise in seasonal coronaviruses Driving global sales – new customers in Europe and USA previously difficult to convert. Now interested in other EasyScreen™ tests De
Slide 9: Regional Summary
Regional Summary Investor DOCUMENT Presentation SEPTEMBER TITLE OCTOBER 2021 Europe North America Australia/NZ ~35% of molecular diagnostics Largest market, ~40% of Head office, R&D, market PCR testing revenue manufacturing Direct sales in Germany & UK, Direct US sales, sales & Direct sales – est. 1
Slide 10: FDA 510(k) Clearance Program
Investor DOCUMENT Presentation TITLE FDA 510(k) Clearance Program SEPTEMBER OCTOBER 2021 Market Dynamics Est. 5.5m Enteric Protozoan tests per annum in the US Current methodology is microscopy – slow and inaccurate Initial focus on largest 30 “high throughput” centralised labs Smaller decentralised
Slide 11: Investment Summary
Investor DOCUMENT Presentation TITLE Investment Summary SEPTEMBER OCTOBER 2021 Financial information Share price (22-Oct-21) A$1.495 Shares on issue 143m Market capitalisation A$214m Ave monthly turnover (shares) 2.2m Cash (30-Sep-21) A$33m Debt (30-Sep-21) Nil Enterprise value A$181m Top shareholde
Slide 12: Looking Forward
Looking Forward Investor DOCUMENT Presentation SEPTEMBER TITLE OCTOBER 2021 Leverage COVID-19 – new customers, new tests Continue building interest in EasyScreen™ kits in US & EU markets using new sales teams and SARS-CoV-2 experience as leverage Targeting high throughput pathology groups, hospitals
Slide 13: Reasons to Invest
Reasons to Invest Investor DOCUMENT Presentation SEPTEMBER TITLE OCTOBER 2021 Attractive investment proposition Continued product • Business model with expansion favourable unit economics • 5 product groups in • Increasing international Significant market development recognition via opportunities •
Slide 14: Contact us
Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 14
Genetic Signatures — Investor Presentation (October 2021) on 6ix